Leonardo Massignan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leonardo Massignan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Lutz Ackermann
Georg-August-Universität Göttingen Tammannstraße 2
3 shared publications - Xuefeng Tan
Department of Chemistry City University of Hong Kong Kowloon Tong Hong Kong China
3 shared publications - Donald Fredric Weaver
University Health Network
2 shared publications - João C. A. Oliveira
Institut für Organische und Biomolekulare Chemie and Wöhler Research Institute for Sustainable Chemistry (WISCh), Georg-August-Universität Göttingen, Tammannstraße 2, 37077, Göttingen, Germany
2 shared publications - Johanna Frey
CNRS‐Université de Strasbourg Institut de Physique et Chimie de Strasbourg, UMR7504 23 rue du Loess—BP43 67034 Strasbourg Cedex 2 France
2 shared publications - Mark A. Reed
University Health Network
2 shared publications
Latest Publications
- 10 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 23111-23226
Enzyme−Targeted Therapeutics for Neurological Disorders
Neurological disorders represent one of the leading causes of disability and mortality worldwide, and their prevalence is expected to increase substantially with population aging. Despite major advances in neuroscience, effective disease-modifying therapies remain unavailable for most chronic disorders of the central nervous system (CNS), highlighting the need for novel therapeutic strategies. Enzymes are attractive drug targets because they regulate fundamental processes including neurotransmission, signal transduction, energy metabolism, protein homeostasis, epigenetic regulation, lipid metabolism, and cellular detoxification. This review summarizes the major classes of druggable CNS enzymes, discuss clinically approved drugs and emerging investigational agents, and evaluate therapeutic opportunities across neurodegenerative, neurodevelopmental, neuropsychiatric, cerebrovascular, and neuro-oncologic diseases. Key challenges including blood−brain barrier penetration, target selectivity, off-target pharmacology, and clinical translation are also examined. By integrating diverse enzyme-targeting modalities across multiple neurological disorders, this review highlights both the progress achieved to date and the substantial opportunities that remain for future CNS drug discovery.
- 10 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 23111-23226
Enzyme−Targeted Therapeutics for Neurological Disorders
Neurological disorders represent one of the leading causes of disability and mortality worldwide, and their prevalence is expected to increase substantially with population aging. Despite major advances in neuroscience, effective disease-modifying therapies remain unavailable for most chronic disorders of the central nervous system (CNS), highlighting the need for novel therapeutic strategies. Enzymes are attractive drug targets because they regulate fundamental processes including neurotransmission, signal transduction, energy metabolism, protein homeostasis, epigenetic regulation, lipid metabolism, and cellular detoxification. This review summarizes the major classes of druggable CNS enzymes, discuss clinically approved drugs and emerging investigational agents, and evaluate therapeutic opportunities across neurodegenerative, neurodevelopmental, neuropsychiatric, cerebrovascular, and neuro-oncologic diseases. Key challenges including blood−brain barrier penetration, target selectivity, off-target pharmacology, and clinical translation are also examined. By integrating diverse enzyme-targeting modalities across multiple neurological disorders, this review highlights both the progress achieved to date and the substantial opportunities that remain for future CNS drug discovery.
- 14 October 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 6010-6019
Development of small molecule inhibitors of ECM collagen secretion
Tissue fibrosis is a common consequence of many different acute and chronic injuries, which severely impairs the function of affected organs. A significant challenge is the lack of effective strategies to treat fibrotic disorders. The metabolic dysregulation underlying fibrosis may be reversed by the small molecule caffeic acid phenethyl ester (CAPE), but there are limitations which prevent its clinical use. Following the identification of caffeic acid derivative 1 from an in-house library screen, we performed structure–activity relationship studies which led to the discovery of novel small molecule inhibitors of extracellular matrix (ECM) collagen secretion. The small molecules increased PPARG and CD36 expression (markers of fatty acid metabolism), suggesting a mechanism of action involving a metabolic shift from fibrotic-to-normal state. The compounds identified in this study provide a foundation for further development towards a novel, first-in-class therapeutic agent for fibrosis.
- 14 October 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 6010-6019
Development of small molecule inhibitors of ECM collagen secretion
Tissue fibrosis is a common consequence of many different acute and chronic injuries, which severely impairs the function of affected organs. A significant challenge is the lack of effective strategies to treat fibrotic disorders. The metabolic dysregulation underlying fibrosis may be reversed by the small molecule caffeic acid phenethyl ester (CAPE), but there are limitations which prevent its clinical use. Following the identification of caffeic acid derivative 1 from an in-house library screen, we performed structure–activity relationship studies which led to the discovery of novel small molecule inhibitors of extracellular matrix (ECM) collagen secretion. The small molecules increased PPARG and CD36 expression (markers of fatty acid metabolism), suggesting a mechanism of action involving a metabolic shift from fibrotic-to-normal state. The compounds identified in this study provide a foundation for further development towards a novel, first-in-class therapeutic agent for fibrosis.
- Open Access
- 2 March 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (24) , 13373-13379
Rhodaelektrokatalysierte bimetallische C‐H‐Oxygenierung durch schwache O‐Koordination
Rhodaelektrokatalysierte C‐H‐Oxygenierungen von Aromaten durch schwach O‐koordinierende Amide und Ketone wurden mittels bimetallischer Elektrokatalyse ermöglicht. Außerdem ermöglichte die sorgfältige Auswahl der Stromstärke den Zugang zu Dihydrooxazinonen durch zweifache C‐H‐Funktionalisierung. Detaillierte experimentelle mechanistische Studien sowie massenspektrometrische und cyclovoltammetrische Analysen deuten auf eine neuartige, elektrooxidativ eingeleitete C‐H‐Funktionalisierung durch bimetallische Rhodiumkatalyse hin.
- 2 March 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (24) , 13373-13379
Open AccessRhodaelektrokatalysierte bimetallische C‐H‐Oxygenierung durch schwache O‐Koordination
Rhodaelektrokatalysierte C‐H‐Oxygenierungen von Aromaten durch schwach O‐koordinierende Amide und Ketone wurden mittels bimetallischer Elektrokatalyse ermöglicht. Außerdem ermöglichte die sorgfältige Auswahl der Stromstärke den Zugang zu Dihydrooxazinonen durch zweifache C‐H‐Funktionalisierung. Detaillierte experimentelle mechanistische Studien sowie massenspektrometrische und cyclovoltammetrische Analysen deuten auf eine neuartige, elektrooxidativ eingeleitete C‐H‐Funktionalisierung durch bimetallische Rhodiumkatalyse hin.
- Open Access
- 2 March 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (24) , 13264-13270
Rhoda‐Electrocatalyzed Bimetallic C−H Oxygenation by Weak O‐Coordination
Rhodium‐electrocatalyzed arene C−H oxygenation by weakly O‐coordinating amides and ketones have been established by bimetallic electrocatalysis. Likewise, diverse dihydrooxazinones were selectively accessed by the judicious choice of current, enabling twofold C−H functionalization. Detailed mechanistic studies by experiment, mass spectroscopy and cyclovoltammetric analysis provided support for an unprecedented electrooxidation‐induced C−H activation by a bimetallic rhodium catalysis manifold.
- 2 March 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (24) , 13264-13270
Open AccessRhoda‐Electrocatalyzed Bimetallic C−H Oxygenation by Weak O‐Coordination
Rhodium‐electrocatalyzed arene C−H oxygenation by weakly O‐coordinating amides and ketones have been established by bimetallic electrocatalysis. Likewise, diverse dihydrooxazinones were selectively accessed by the judicious choice of current, enabling twofold C−H functionalization. Detailed mechanistic studies by experiment, mass spectroscopy and cyclovoltammetric analysis provided support for an unprecedented electrooxidation‐induced C−H activation by a bimetallic rhodium catalysis manifold.
- Open Access
- 28 November 2019
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 59 (8) , 3184-3189
C−H Oxygenation Reactions Enabled by Dual Catalysis with Electrogenerated Hypervalent Iodine Species and Ruthenium Complexes
The catalytic generation of hypervalent iodine(III) reagents by anodic electrooxidation was orchestrated towards an unprecedented electrocatalytic C−H oxygenation of weakly coordinating aromatic amides and ketones. Thus, catalytic quantities of iodoarenes in concert with catalytic amounts of ruthenium(II) complexes set the stage for versatile C−H activations with ample scope and high functional group tolerance. Detailed mechanistic studies by experiment and computation substantiate the role of the iodoarene as the electrochemically relevant species towards C−H oxygenations with electricity as a sustainable oxidant and molecular hydrogen as the sole by‐product. para‐Selective C−H oxygenations likewise proved viable in the absence of directing groups.
- 28 November 2019
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 59 (8) , 3184-3189
Open AccessC−H Oxygenation Reactions Enabled by Dual Catalysis with Electrogenerated Hypervalent Iodine Species and Ruthenium Complexes
The catalytic generation of hypervalent iodine(III) reagents by anodic electrooxidation was orchestrated towards an unprecedented electrocatalytic C−H oxygenation of weakly coordinating aromatic amides and ketones. Thus, catalytic quantities of iodoarenes in concert with catalytic amounts of ruthenium(II) complexes set the stage for versatile C−H activations with ample scope and high functional group tolerance. Detailed mechanistic studies by experiment and computation substantiate the role of the iodoarene as the electrochemically relevant species towards C−H oxygenations with electricity as a sustainable oxidant and molecular hydrogen as the sole by‐product. para‐Selective C−H oxygenations likewise proved viable in the absence of directing groups.